Evotec creates long-term growth opportunities
Campus Levi-Montalcini is one of Evotec’s fully integrated powerhouses that offers expertise, capacity, capabilities and know-how in integrated R&D.
The site comprises all technologies and services needed to develop a drug discovery project from the idea, through pre-clinical and clinical development, all the way to the market – including INDiGO, the Company’s integrated and interdisciplinary service for accelerated drug development as well as broad and deep expertise in API manufacturing, pre-formulation and cGMP manufacturing of the drug product.
Evotec has been operating at its Verona site since acquiring Aptuit in 2017 and currently employs approximately 750 employees on Campus Levi-Montalcini. Both the existing buildings as well as the plot hold further potential to enter the next growth phase in Verona and continue to build capacity as needed to support the Company’s global strategic framework Action Plan 2025: “The data-driven R&D Autobahn to Cures”.
Dr Werner Lanthaler, Chief Executive Officer of Evotec, commented: “Evotec is committed to its vision of efficiently delivering new and highly effective therapeutics to patients who urgently need them. In order to truly deliver on this mission, our sustainable growth strategy builds on complementary clusters of excellence. Acquiring the site will give us plenty of opportunities to further grow our business in Verona and we are proud to call the site Campus Levi-Montalcini.”
Dr Ciriaco Maraschiello, EVP, Global Head of Drug Development and Verona Site Head, added: “The acquisition of the Verona R&D campus from GSK, one of the major R&D centres in the country, means continuity and further development of R&D excellence in Italy. Becoming the owner of the Verona R&D facility strengthens Evotec’s fully integrated R&D solutions for our partners. This is also an opportunity to create the right environment on site to continue to be the best at what we do every day; contributing to the discovery and development of better medicines and ultimately improving the quality of life for patients.”
Biotech & Pharma
Sysmex Europe SE is listed in the top 100 best workplaces
Biotech & Pharma